https://www.selleckchem.com/pr....oducts/protoporphyri
Patients with Ewing's sarcoma family of tumors (ESFT) who experience relapse or progression have a poor prognosis. This study aimed to identify the prognostic and therapeutic factors affecting overall survival (OS) of patients with recurrent or refractory localized ESFT. Thirty-eight patients with localized ESFT who experienced first relapse or progression between 2000 and 2018 were retrospectively reviewed. The 5-year OS rate of the entire cohort was 48.3% (95% confidence interval, 29.9%-64.5%). Multivariate analysis of OS id
Like
Comment
Share
